1,247 results match your criteria Aspergillosis Thoracic

Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy.

J Mycol Med 2022 Jun 15;32(4):101304. Epub 2022 Jun 15.

Uludağ University Faculty of Medicine, Department of Hematology, Bursa, Turkey.

Introduction: The first consensus definitions for invasive fungal diseases (IFD) were published in 2002. Advances in diagnostic tests and a clear need for improvement in certain areas led to a revision of these definitions in 2008. However, growing data on Aspergillus galactomannan (GM) thresholds and the introduction of new polymerase chain reaction-based diagnostic tests resulted in a further update by EORTC and Mycoses Study Group Education and Research Consortium (MSGERC) in 2020. Read More

View Article and Full-Text PDF

Aspergillus pleural empyema in a chronic smoker - A case report and review of literature.

J Mycol Med 2022 May 23;32(4):101299. Epub 2022 May 23.

Division of Infectious Diseases, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York 11030, USA.

Aspergillus species are ubiquitous saprophytic fungi that are present in the air, water, soil, and decaying vegetables. Clinical features of Aspergillus infection largely depend on the interplay between the fungi and the host immune status. We present a case of a chronic smoker with shortness of breath who was found to have diffuse bronchiectatic changes and empyema of the right lung. Read More

View Article and Full-Text PDF

Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.

Clin Transplant 2022 May 16:e14709. Epub 2022 May 16.

Department of Medical Microbiology, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.

Background: Voriconazole is the first line treatment for invasive aspergillosis (IA) Current guidelines suggest performing regular voriconazole therapeutic drug monitoring (TDM) to optimize treatment efficacy. We aimed to determine if TDM was predictive of clinical outcome in LTRs.

Methods: Retrospective chart review was performed for all LTRs with probable or proven IA, treated with voriconazole monotherapy and who underwent TDM during therapy. Read More

View Article and Full-Text PDF

Improved absorption of itraconazole tablet by co-administration with lemon beverages in a lung transplant recipient: A case report.

J Infect Chemother 2022 Aug 7;28(8):1203-1207. Epub 2022 May 7.

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin- Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address:

After lung transplantation, itraconazole (ITCZ) is used as a prophylaxis for aspergillosis. ITCZ is a weak base with high lipophilicity, and the dissolution and absorption of ITCZ tablets and capsules are pH dependent. Therefore, ITCZ may not achieve sufficient serum concentrations in patients with higher gastric pH because of its poor bioavailability. Read More

View Article and Full-Text PDF

Invasive Fungal Pneumonia in Immunocompromised Patients.

Radiol Clin North Am 2022 May;60(3):497-506

Department of Diagnostic Radiology, The Chaim Sheba Medical Center, Affiliated with the Tel Aviv University, 2 Derech Sheba St, Ramat Gan 5265601, Israel.

Fungal pneumonia is the most frequent presentation of invasive fungal infections (IFIs) in patients with hematologic malignancies (HM) and hematopoietic stem cell transplantation (HSCT) recipients. The most common causes include Aspergillus, Mucor, Fusarium, and Candida species. The high incidence and high morbidity and mortality rate of fungal pneumonias in HM/HSCT populations arise from severe immune dysfunction that may be caused by both the underlying disease and/or its treatment. Read More

View Article and Full-Text PDF

Pulmonary aspergilloma in immunocompromised patients in a Respiratory Care Unit.

J Infect Dev Ctries 2022 03 31;16(3):564-569. Epub 2022 Mar 31.

Pneumology and Thorax Surgery Service, General Hospital of Mexico, Dr. Eduardo Liceaga, Mexico City, Mexico.

Introduction: Pulmonary aspergilloma is commonly associated with comorbidities that cause immunodeficiency such as diabetes mellitus, tuberculosis, human immunodeficiency virus/acquired immunodeficiency syndrome and/or a pre-existing parenchymal lung disease such as chronic obstructive pulmonary disease. Predisposing factors can further increase the risk of acquiring this mycosis. Our objective was to determine the frequency, clinical and microbiological characteristics of pulmonary aspergilloma in immunocompromised patients. Read More

View Article and Full-Text PDF

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Lancet Infect Dis 2022 Apr 4. Epub 2022 Apr 4.

Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:

COVID-19-associated pulmonary mucormycosis (CAPM) remains an underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus statement for the diagnosis and management of CAPM. We selected 26 experts from various disciplines who are involved in managing CAPM. Read More

View Article and Full-Text PDF

Azole-Induced Myositis after Combined Lung-Liver Transplantation.

Case Rep Transplant 2022 25;2022:7323755. Epub 2022 Mar 25.

Department of Respiratory Diseases and Lung Transplantation, University Hospital Gasthuisberg, Leuven, Belgium.

Lung transplant recipients experience a high rate of invasive pulmonary aspergillosis infections, for which voriconazole is the treatment of choice. We report a patient who developed voriconazole-induced myositis that relapsed after one dose of isavuconazole. Our patient was a 38-year-old man who received a single sequential lung transplantation and liver transplantation because of end-stage cystic fibrosis. Read More

View Article and Full-Text PDF

Fatal Early-Onset Aspergillosis in a Recipient Receiving Lungs From a Marijuana-Smoking Donor: A Word of Caution.

Transpl Int 2022 14;35:10070. Epub 2022 Feb 14.

Thoracic Surgery and Lung Transplant Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.

View Article and Full-Text PDF

COVID-19 Associated Pulmonary Aspergillosis: Diagnostic Performance, Fungal Epidemiology and Antifungal Susceptibility.

J Fungi (Basel) 2022 Jan 18;8(2). Epub 2022 Jan 18.

Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, A-6020 Innsbruck, Austria.

Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) raises concerns as to whether it contributes to an increased mortality. The incidence of CAPA varies widely within hospitals and countries, partly because of difficulties in obtaining a reliable diagnosis. We implemented a routine screening of respiratory specimens in COVID-19 ICU patients for species using culture and galactomannan (GM) detection from serum and/or bronchoalveolar lavages (BAL). Read More

View Article and Full-Text PDF
January 2022

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).

Microbiol Spectr 2022 02 16;10(1):e0178421. Epub 2022 Feb 16.

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Isavuconazole (ISA) is an alternative treatment for Aspergillus spp. and other fungal infections, but evidence regarding its use in solid organ transplant recipients (SOTR) is scarce. All SOTR who received ISA for treatment of a fungal infection (FI) at our center from December 2017 to January 2021 were included. Read More

View Article and Full-Text PDF
February 2022

Serum total IgE may be a biomarker among chronic pulmonary aspergillosis patients with elevated serum total IgE levels: A cohort study with pathological evaluations.

Med Mycol 2022 Mar;60(3)

Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Kiyose-shi, Tokyo, 204-8585, Japan.

High serum total immunoglobulin E (IgE) levels have been reported in chronic pulmonary aspergillosis (CPA). However, researchers have not verified if they reflect the disease activity. We aimed to compare the serum total IgE levels in CPA cases with high serum IgE during an exacerbation or when stable and examined the IgE expression patterns in the lesions via immunofluorescence staining. Read More

View Article and Full-Text PDF

Successful treatment of angioinvasive aspergillosis causing diaphragmatic rupture with bowel perforation and cerebral aspergillosis in a patient with FLT3-mutated acute myeloid leukemia: A case report.

Medicine (Baltimore) 2022 Jan;101(4):e28700

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Rationale: Throughout the clinical course of acute myeloid leukemia (AML), aspergillosis infection remains a significant determinant of treatment outcomes and survival. To emphasize the importance of early diagnosis and appropriate application of integrated therapeutic approaches, we present a case of AML patient who survived through angioinvasive aspergillosis infection causing diaphragmatic rupture with bowel perforation and cerebral aspergillosis during active AML treatment.

Patient Concerns: A 39-year old male with FLT3-mutated AML was transferred to our hospital due to persistent fever after induction therapy. Read More

View Article and Full-Text PDF
January 2022

Emergency pulmonary resection in massive hemoptysis: analysis of 39 patients.

Kardiochir Torakochirurgia Pol 2021 Dec 9;18(4):203-209. Epub 2022 Jan 9.

Department of Thoracic Surgery, Health Sciences University, Dr Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey.

Introduction: The mortality of massive hemoptysis is high, and it is important to make quick decisions. Emergency pulmonary resection continues to be a mandatory option when conservative methods cannot prevent massive hemoptysis, as it is life-threatening.

Aim: We report our experience with patients undergoing pulmonary resection for massive hemoptysis. Read More

View Article and Full-Text PDF
December 2021

Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study.

BMC Pulm Med 2022 Jan 19;22(1):40. Epub 2022 Jan 19.

Department of Thoracic Surgery, Shandong Public Health Clinical Center, No.2999, GangXing Xi Road, Jinan, Shandong, China.

Background: The reported experience of surgical treatment for chronic pulmonary aspergillosis (CPA) mainly focused on simple aspergilloma (SA), few about other types of CPA. The present study aims to evaluate the outcomes of surgical treatment for different types of CPA.

Methods: We performed a retrospective analysis of 85 patients with CPA who underwent surgery from 2014 to 2020 at Shandong Provincial Chest Hospital. Read More

View Article and Full-Text PDF
January 2022

Proven pulmonary aspergillosis in a COVID-19 patient: A case report.

Curr Med Mycol 2021 Jun;7(2):39-42

Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Background And Purpose: Coronavirus disease 2019 (COVID-19) has become a significant clinical challenge in healthcare settings all over the world. Critically ill COVID-19 patients with acute respiratory distress syndrome may be at increased risk of co-infection with pulmonary aspergillosis. This study aimed to describe a clinical case of proven pulmonary aspergillosis caused by in a 59-year-old man with a history of hospitalization due to COVID-19 infection. Read More

View Article and Full-Text PDF

Incidental Finding of an Aspergillus Pseudoaneurysm in the Ascending Aorta of an Immunocompetent Patient.

Int Med Case Rep J 2021 22;14:843-847. Epub 2021 Dec 22.

Department of Medicine, Fakeeh College of Medical Sciences, Jeddah, Kingdom of Saudi Arabia.

Pseudoaneurysms of the ascending aorta are rare, yet they are life-threatening conditions and usually associated with poor outcomes due to insidious presentation. Many different etiologies have been associated with aortic pseudoaneurysms including; atherosclerosis, infections, connective tissue disorders, and traumatic causes. In addition, aortic pseudoaneurysms have been reported following thoracic surgeries, including aortic valve replacements, aortic dissection repair, and coronary artery bypass grafting. Read More

View Article and Full-Text PDF
December 2021

Chronic Pulmonary Aspergillosis and Type 2 Diabetes Mellitus Complicating Granulomatosis with Polyangiitis in an Adult Saudi Male: A Case Report.

Int Med Case Rep J 2021 20;14:829-837. Epub 2021 Dec 20.

Almoosa Specialist Hospital, Al Ahsa, Saudi Arabia.

Background: Granulomatosis with polyangiitis (GPA) is an extremely rare autoimmune, necrotizing granulomatous disease of unknown etiology affecting small and medium-sized blood vessels. Chronic pulmonary aspergillosis (CPA) is a rare fungal infection with high morbidity and mortality that usually affects immunocompetent or mildly immunosuppressed patients with underlying respiratory disease. Antifungal agents (voriconazole, itraconazole) are the mainstay of therapy. Read More

View Article and Full-Text PDF
December 2021

Total unilateral pulmonary collapse secondary to allergic bronchopulmonary aspergillosis: a case series of an unusual cause of complete atelectasis.

BMC Pulm Med 2021 Dec 24;21(1):425. Epub 2021 Dec 24.

Nantes Université, CHU Nantes, Service de Pneumologie, L'Institut du thorax, Nantes, 44000, France.

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a bronchopulmonary disease caused by a complex hypersensitivity to Aspergillus and is usually associated with underlying respiratory diseases such as asthma or cystic fibrosis. Mucus plugging can lead to segmental or lobar atelectasis, but complete lung atelectasis has been exceptionally reported in the literature, making it difficult to diagnose. The diagnosis of ABPA may however be suggested in patients without known predisposing respiratory disorder, even in the absence of other relevant radiographic findings. Read More

View Article and Full-Text PDF
December 2021

A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL).

Thorax 2021 Nov 30. Epub 2021 Nov 30.

Manchester Fungal Infection Group, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Objectives: Chronic pulmonary aspergillosis (CPA) can complicate recovery from pulmonary TB. CPA may also be misdiagnosed as bacteriologically negative TB. This study aimed to determine the incidence of CPA in patients treated for TB in Indonesia, a country with a high incidence of TB. Read More

View Article and Full-Text PDF
November 2021

Endobronchial valve placement in secondary pneumothorax related to allergic bronchopulmonary aspergillosis.

Respir Med Case Rep 2021 10;34:101554. Epub 2021 Nov 10.

Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Secondary pneumothorax is a rare but serious complication of allergic bronchopulmonary aspergillosis (ABPA) and bronchiectasis [1,2]. Persistent air leak (PAL) after secondary pneumothorax is an ongoing abnormal communication between bronchi or alveoli and the pleural space, despite drainage. Ongoing PAL for 5 days after initial chest tube insertion necessitates prolonged ambulatory drainage or aggressive management with video-assisted thoracoscopic surgery (VATS) or pleurodesis [3,4]. Read More

View Article and Full-Text PDF
November 2021

Pre-operative endovascular coil embolisation for chronic pulmonary aspergillosis.

Int J Tuberc Lung Dis 2021 09;25(9):725-731

Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, Tokyo, Japan.

To retrospectively evaluate the clinical outcomes of pre-operative endovascular coil embolisation (ECE) for chronic pulmonary aspergillosis (CPA). We evaluated surgical patients with CPA between November 2016 and April 2020. Pre-operative ECE for CPA with severe adhesions was selectively performed to reduce intra-operative blood loss. Read More

View Article and Full-Text PDF
September 2021

The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single-centre study.

Mycoses 2022 Feb 27;65(2):164-170. Epub 2021 Nov 27.

Division of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan.

Background: Aspergillus spp. is identified morphologically without antifungal susceptibility tests (ASTs) in most clinical laboratories. The aim of this study was to examine the clinical impact of the morphological identification of Aspergillus spp. Read More

View Article and Full-Text PDF
February 2022

Epidemiology and Prognosis of Invasive Fungal Disease in Chinese Lung Transplant Recipients.

Front Med (Lausanne) 2021 27;8:718747. Epub 2021 Oct 27.

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

This study explored the epidemiology, risk factors, and prognosis of invasive fungal disease (IFD) in Chinese lung transplant recipients (LTRs). This retrospective cohort study included patients who received lung transplants at four hospitals in South China between January 2015 and June 2019. The participants were divided into IFD and non-IFD (NIFD) groups. Read More

View Article and Full-Text PDF
October 2021

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.

Eur Respir J 2022 Jun 16;59(6). Epub 2022 Jun 16.

Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique, Centre Constitutif Maladies Pulmonaires Rares and Sorbonne Université, Paris, France.

Background: In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission.

Methods: We performed a randomised, single-blind, clinical trial in 30 centres. Patients with controlled ABPA after 4-month attack treatment (corticosteroids and itraconazole) were randomly assigned to nebulised liposomal amphotericin-B or placebo for 6 months. Read More

View Article and Full-Text PDF

The effects of antifungal therapy on the recurrence of aspergillus infection after pulmonary aspergilloma resection: a study protocol for a single-center, prospective, non-blind, randomized, 24-month, parallel group study.

BMC Pulm Med 2021 Oct 29;21(1):335. Epub 2021 Oct 29.

Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zheng Min Road, Shanghai, 200433, China.

Background: In recent years, the incidence of pulmonary aspergilloma has increased. The harm of aspergilloma is life-threatening massive hemoptysis, and the conventional treatment is surgical treatment. However, whether the antifungal treatment after surgery is required and the course of treatment before and after surgery are still unclear. Read More

View Article and Full-Text PDF
October 2021

Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting.

J Intensive Care Med 2021 Oct 22:8850666211047166. Epub 2021 Oct 22.

30093Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India.

Coronavirus disease-2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a new disease characterized by secondary mold infection in patients with COVID-19. It primarily affects patients with COVID-19 in critical state with acute respiratory distress syndrome, requiring intensive care and mechanical ventilation. CAPA has a higher mortality rate than COVID-19, posing a serious threat to affected individuals. Read More

View Article and Full-Text PDF
October 2021

Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxis.

J Infect Chemother 2022 Jan 11;28(1):54-60. Epub 2021 Oct 11.

Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin- Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address:

Introduction: Invasive Aspergillus infection (IA) in lung transplantation can result in poor outcomes. Itraconazole has been shown to be effective for fungal prophylaxis in lung transplant recipients. However, IA remains a major cause of death after lung transplantation. Read More

View Article and Full-Text PDF
January 2022